Diann Blanset

<i>In Vitro</i> Characterization of the Anti-PD-1 Antibody Nivolumab, BMS-936558, and <i>In Vivo</i> Toxicology in Non-Human Primates

Changyu Wang, Kent Thudium, Minhua Han et al. · Cancer Immunology Research · 2014 · 585 citations

Phase I/II Study of an Anti-CD30 Monoclonal Antibody (MDX-060) in Hodgkin's Lymphoma and Anaplastic Large-Cell Lymphoma

Stephen M. Ansell, Steven M. Horwitz, Andreas Engert et al. · Journal of Clinical Oncology · 2007 · 251 citations

A novel BCMA/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo

Susanne Hipp, YT Tai, Diann Blanset et al. · Leukemia · 2016 · 228 citations · Full text

Hematological Malignancy, Cancer Immunosurveillance, Malignant Blood Disorder +11

Preclinical Development of Ipilimumab and Nivolumab Combination Immunotherapy: Mouse Tumor Models, In Vitro Functional Studies, and Cynomolgus Macaque Toxicology

Mark Selby, John Engelhardt, Robert J. Johnston et al. · PLoS ONE · 2016 · 225 citations · Full text

Immunology, Pathology, Immunotherapeutics +18

CTLA-4 blockade decreases TGF-beta, IDO, and viral RNA expression in tissues of SIVmac251-infected macaques

Anna Hryniewicz, Adriano Boasso, Yvette Edghill‐Smith et al. · Blood · 2006 · 165 citations · Full text